Journal
JOURNAL OF NEUROIMMUNOLOGY
Volume 232, Issue 1-2, Pages 136-144Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jneuroim.2010.10.031
Keywords
Glatiramer acetate; Inflammation; B cells; CD19; CD5
Categories
Funding
- Teva Pharmaceuticals, LTD, Petah Tiqva, Israel [R01 AI061938 - NIAID]
- National Multiple Sclerosis Society [CA1027A1/3]
Ask authors/readers for more resources
We recently showed that B cells reduce CNS inflammation in mice with experimental allergic encephalomyelitis (EAE). Here, we demonstrate that adoptively transferred CD5/CD19+ B cells protect against EAE severity. Furthermore, we show that glatiramer acetate (GA), a therapeutic for relapsing multiple sclerosis treatment, amplifies this effect. Transfer of GA-conditioned B cells leads to increased production of immunoregulatory cytokines and reduced CNS inflammation, as well as decreased expression of the chemokine receptor, CXCR5, and elevated BDNF expression in the CNS. Thus B cells can protect against EAE, and GA augments this effect in maintaining immune homeostasis and controlling EAE disease progression. (C) 2010 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available